FA
Fabtech Technologies Ltd (FABTECH)
₹123.90
Mkt cap
₹551 Cr
P/E ratio
18.50
P/B
1.25
Div yield
0.48%
ROE
12.00%
ROCE
13.90%
EPS (TTM)
₹6.70
Book value
₹99
52W range
115–263
Sector
Healthcare
Price history
Previous close
Incorporated in 2018, Fabtech Technologies Ltd is a biopharma engineering company. [1]
NSE FABTECHBSE 544558
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthHigh
TechnicalsBearish
52-week range
−52.85% from high₹124
₹115+7.65% from low₹263
Current
₹123.90
Prev close
₹122.21
Day
+1.38%
Price performance
1D
+2.61%
1W
+4.53%
1M
−14.97%
3M
−16.44%
6M
−26.76%
1Y
−39.16%
YTD
−37.48%
Financials
Revenue, profit & margin
P/E ratio
18.5×
FABTECH is 38% below the sector median of 30.0×
FABTECH18.5×
Sector median30.0×
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 59 | 104 | 135 | 68 | 121 | 63 | 159 | 75 | 92 | |
| Expenses | 54 | 81 | 116 | 74 | 91 | 74 | 136 | 71 | 82 | |
| Operating Profit | 5 | 23 | 18 | -6 | 30 | -12 | 22 | 4 | 10 | |
| OPM % | 8% | 22% | 14% | -9% | 25% | -18% | 14% | 6% | 11% | |
| Other Income | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 3 | 14 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Profit before tax | 6 | 24 | 20 | -6 | 31 | -7 | 30 | 5 | 22 | |
| Tax % | 15% | 13% | 24% | -1% | 10% | -15% | 26% | 20% | 31% | |
| Net Profit | 5 | 20 | 15 | -6 | 28 | -6 | 22 | 4 | 15 | |
| EPS in Rs | 1.58 | 6.32 | 4.66 | -1.89 | 8.68 | -1.28 | 4.96 | 0.95 | 3.38 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202669.03%Promoter
Promoters69.03%0.09
FIIs0.02%
DIIs2.45%
Public28.49%0.08
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Syngene Intl. | ₹402.70 | 61.15 | 16,256 | 0.31% | 32 | −45.17% | 833 | −8.55% | 9.99% |
| Indegene | ₹586.80 | 33.16 | 14,141 | 0.38% | 112 | +9.99% | 1,122 | +39.55% | 18.82% |
| Suven Life Scie. | ₹258.85 | — | 7,314 | 0.00% | −128 | −147.69% | 4 | +90.91% | −79.54% |
| Vimta Labs | ₹484.90 | 26.60 | 2,168 | 0.41% | 21 | +3.46% | 112 | +9.95% | 25.23% |
| Fabtech Tech. | ₹123.90 | 18.50 | 551 | 0.48% | 15 | −67.06% | 92 | −24.19% | 13.88% |
| Novelix Pharma. | ₹68.57 | 53.93 | 195 | 0.00% | 1 | +972.73% | 37 | +65.15% | 10.87% |
| Bilcare | ₹75.33 | 8.91 | 177 | 0.00% | 15 | +473.06% | 226 | +21.20% | 7.06% |
| Median: 9 Co. | ₹123.90 | 29.95 | 551 | 0.00% | 15 | +9.99% | 92 | +30.38% | 10.87% |
Filings
Annual reports1
Concall transcripts14
Credit ratings3
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Oct - Recorded earnings conference call for Q2 and half-year FY2026 results available online.Announcement under Regulation 30 (LODR)-Newspaper Publication 30 OctAnnouncement under Regulation 30 (LODR)-Investor Presentation 30 Oct - Please find attached Investor Presentation in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half- year ended …Announcement under Regulation 30 (LODR)-Press Release / Media Release 28 Oct - Fabtech reported Q2 FY27 revenue of ₹920.9 million and H1 FY27 PAT of ₹192.4 million; order book ~₹900 crore.Announcement under Regulation 30 (LODR)-Change in Management 28 Oct - Board approved Q2 FY27 unaudited results and appointed Alan Dias as Senior Management Personnel effective immediately.